Pro-neural transcription factors as cancer markers by Vias, Maria et al.
BioMed CentralBMC Medical Genomics
ssOpen AcceResearch article
Pro-neural transcription factors as cancer markers
Maria Vias1, Charlie E Massie1, Philip East2, Helen Scott1, Anne Warren3, 
Zongxiang Zhou4, Alexander Yu Nikitin4, David E Neal†1 and Ian G Mills*†1
Address: 1Uro-Oncology Research Group, Cancer Research UK Cambridge Research Institute, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 
0RE, UK, 2Bioinformatics & Biostatistics, Cancer Research UK London Research Institute, 44 Lincoln's Inn Fields, London, WC2A 3PX, UK, 
3Department of Pathology, Addenbrookes Hospital, Cambridge, CB2 2QQ, UK and 4Department of Biomedical Sciences, Cornell University, 
Ithaca, New York, 14853, USA
Email: Maria Vias - maria.vias@cancer.org.uk; Charlie E Massie - charlie.massie@cancer.org.uk; Philip East - phil.east@cancer.org.uk; 
Helen Scott - helen.scott@cancer.org.uk; Anne Warren - ayw23@cam.ac.uk; Zongxiang Zhou - zz34@cornell.edu; 
Alexander Yu Nikitin - an58@cornell.edu; David E Neal - den22@cam.ac.uk; Ian G Mills* - ian.mills@cancer.org.uk
* Corresponding author    †Equal contributors
Abstract
Background: The aberrant transcription in cancer of genes normally associated with embryonic
tissue differentiation at various organ sites may be a hallmark of tumour progression. For example,
neuroendocrine differentiation is found more commonly in cancers destined to progress, including
prostate and lung. We sought to identify proteins which are involved in neuroendocrine
differentiation and differentially expressed in aggressive/metastatic tumours.
Results: Expression arrays were used to identify up-regulated transcripts in a neuroendocrine
(NE) transgenic mouse model of prostate cancer. Amongst these were several genes normally
expressed in neural tissues, including the pro-neural transcription factors Ascl1 and Hes6. Using
quantitative RT-PCR and immuno-histochemistry we showed that these same genes were highly
expressed in castrate resistant, metastatic LNCaP cell-lines. Finally we performed a meta-analysis
on expression array datasets from human clinical material. The expression of these pro-neural
transcripts effectively segregates metastatic from localised prostate cancer and benign tissue as well
as sub-clustering a variety of other human cancers.
Conclusion: By focussing on transcription factors known to drive normal tissue development and
comparing expression signatures for normal and malignant mouse tissues we have identified two
transcription factors, Ascl1 and Hes6, which appear effective markers for an aggressive phenotype
in all prostate models and tissues examined. We suggest that the aberrant initiation of
differentiation programs may confer a selective advantage on cells in all contexts and this approach
to identify biomarkers therefore has the potential to uncover proteins equally applicable to pre-
clinical and clinical cancer biology.
Background
In recent years there has been much effort to identify new
prostate cancer biomarkers. Malignant prostatic tumours
commonly contain scattered or focal neuroendocrine type
cells, but only a small minority or prostate cancers contain
an homogenous population of such cells, when they are
classified as small cell prostatic carcinoma. However,
other regular prostate carcinomas which have an
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progression and castration resistance [1-3]. We recently
reported that long-term anti-androgen treatment induces
NE differentiation in a cell line model, giving rise to a
more invasive phenotype [4].
Some previous studies have failed to find convincing cor-
relations between focal NE differentiation and prostate
cancer progression [5-7] Variations in expression and
detection of neuron-specific enolase, chromogranin A and
synaptophysin may be partly responsible for this contro-
versy. Therefore better markers for a neural or neuroendo-
crine phenotype would benefit the field.
Multiple basic helix-loop-helix (bHLH) proteins play a
critical role in the regulation of neural stem cell differen-
tiation [8]. The bHLH family of transcription factors
includes activators and repressors of transcription. The
activator-type bHLH transcription factors include 'acha-
ete-scute complex' homologue 1 (Ascl1) which is
expressed in differentiating neurons and belongs to the
Neurogenin Family. This activating bHLH transcription
factor is believed to drive the expression of a 'hairy and
enhancer of split' factor, Hes6. Hes6 in turn can support
Ascl1 activity and neuronal differentiation in part by
antagonising Hes1 activity through heterodimer forma-
tion [9]. Hes1 is a repressor-type bHLH transcription fac-
tor which maintains neural stem cells by repressing
activator bHLH expression [10]. In the case of Hes1 this
occurs at two levels: firstly through direct binding to the
Ascl1 promoter, and secondly by forming a non-func-
tional heterodimer with another activator-type bHLH
transcription factor, E47 [9,11]. Overall, Hes proteins are
involved in the maintenance of neural stem cells and glio-
genesis, whilst Ascl1 is implicated in neurogenesis [12-
14].
Methods
In silico approaches
Expression array data from p53PE-/-; RbPE-/- cancerous (n =
5) and normal (n = 3) samples were retrieved from a pre-
viously published data set [15]. Gene expression data
from the p53PE-/-; RbPE-/- mouse model expression array
data were analysed in the R statistical software using the
limma and affy packages [16,17]. Briefly, data were pre-
processed using the RMA (Robust Multichip Average)
method, before fitting a linear model and applying Baye-
sian smoothing to identify differentially expressed genes
between the normal and cancer samples. M-values (log2
expression ratios) were calculated for all probes and for
each sample and then complete hierarchical clustering
was performed using the Eisen Cluster program [18].
Heatmaps were generated using the Eisen TreeView pro-
gram.
Median centred log2 ratios of normal adult tissue tran-
script levels were retrieved from the Oncogenomics Nor-
mal Tissue Database [19] for genes which were found to
be differentially regulated in the p53PE-/-; RbPE-/- mouse
model of prostate cancer using IMAGE clone identifiers
retrieved from the Clone/Gene ID converter [20,21].
Clinical prostate cancer expression array data were
retrieved from the NCBI Gene Expression Omnibus
(accession numbers GSE3325 and GSE6099) from a pre-
viously published Affymetrix expression array data set. To
generate dot plots, data were pre-processed using the RMA
(Robust Multichip Average) method, quantile normalised
and intensity estimate values were averaged for all probes
for a given gene.
Clinical cancer expression array data sets (ExpO) covering
1786 multi-tissue tumour specimens were retrieved from
the NCBI Gene Expression Omnibus (accession number
GSE2109). Preprocessed MAS5 intensity estimates were
median-centred for each chip and each gene scaled to its
median intensity value across all samples. Log2 neuroen-
docrine biomarker expression vectors across all 1786 sam-
ples were extracted (Hes6, Ascl1, Chga, Ddc, Nts and
Pou5f1). These are displayed as a heatmap. Genes were
functionally grouped (Hes6, Hes6-Chga, Hes6-Ddc, Ascl1,
Ascl1-Hes6-Nts-Ddc) and a median expression intensity
calculated per group for each sample. Samples showing a
greater than 3 fold increase in expression per group were
selected. Selected samples are highlighted by black bars
above the heatmap. Samples assigned to each gene group
were tested for enrichment of malignant tissue type when
compared to the complete dataset using a hyper-geomet-
ric distribution. Enriched tumour types (p-value < 0.05)
are shown in Table 1 and are highlighted as coloured bars
on the heatmap. The analysis was carried out within R
using Bioconductor [16].
Statistical Analysis of the ExpO Dataset
Each chips MAS5 generated signal intensity estimates were
scaled to the chip median. We acknowledge a quantifica-
tion algorithm such as RMA would be a preferable step
here but due to the large size of the data set and available
computational resources this proved problematic. The nor-
malised expression vectors and sample annotation were
databased using MySQL to allow efficient access to the
expression profiles [22]. The DBI package within R was
used to extract neuroendocrine gene profiles
(205311_at:DDC, 206291_at:NTS, 206940_s_at:POU4F1,
209985_s_at:ASCL1, 209987_s_at:ASCL1, 209988_s_at:ASCL1,
211341_at:POU4F1, 213768_s_at:ASCL1, 214347_s_at:DDC,
226446_at:HES6, 228169_s_at:HES6, 204697_s_at:CHGA).
Each gene profile was scaled to its median value across all
samples and a Bioconductor Expression Set object created.
The profiles were grouped into functional gene sets and aPage 2 of 16
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Hes6-Chga, Hes6-Ddc, Ascl1, Ascl1-Hes6-Nts-Ddc). Samples
displaying a greater than 3 fold induction were selected.
Identified samples were then tested for enrichment of
tumour type using a hyper-geometric distribution. (R
code provided below). The function phyper.expo(decide,
pdat, th = 2) is called with a vector (decide) indicating up
regulated, down regulated and unselected genes (1, -1,
and 0 respectively), a dataframe (pdat) containing tumour
type labels etc. as columns and a threshold (tr) setting the
minimum number of tumour type hits within the selected
samples to report. A list is returned containing tumour
label, the number of tumour type samples within the sam-
ple set (hits), the number of tumour type samples within
the ExpO dataset,(foreground), the number of non
tumour type samples within the ExpO dataset (back-
ground), the number of samples selected on expression
(sample.size) and the p-value (p. value) associated with
enrichment.
Quantitative real time polymerase chain reaction (qRT-
PCR)
RNA extraction, cDNA synthesis and qRTPCR were per-
formed as previously described [4]. Primers for quantita-
tive real time polymerase chain reaction using Sybrgreen
chemistry were designed using Primer Express software
(Applied Biosystems) (Table 2). Another set of primer
sequences were used as previously reported like dopa
decarboxylase [23], NeuroD1 and Neurogenin 2 [24],
Hes1 [25], Hes6 [26] and Ascl1 [27].
Small interference RNA silencing
Cells were washed with PBS, trypsinized and centrifuged
at 1300 rpm for 3 minutes. The cell pellet was resus-
pended and cells were counted using the haemocytome-
ter. 2 × 106 cells were mixed with 100 μl of Nucleofector
solution R (Amaxa, GmbH) and 1 μg of siRNA duplexes
was added. Using the Nucleofector program T-09, a spe-
cific electrical current is applied to the cells and the DNA
is delivered into the nucleus. Cells were transferred to cul-
ture dishes containing RPMI media supplemented with
20% FBS to facilitate cell attachment. Media was changed
12 hours after transfection and RNA was extracted from
cells after 24 hours. Hes6 siRNA duplexes were purchased
from Dharmacon (Lafayette, CO). Hes6 siRNA was
designed against the human mRNA of Hes6 (GenBank
accession number NM_018645) and consists of two
selected siRNA duplexes. The target sequence for the
duplex 1 was CAGCCTGACCACAGCCCAA (sense:
CAGCCUGACCACAGCCCAAUU; antisense: 5'-P UUG-
GGCUGUGGUCAGGCUGUU) whereas the target
sequence for duplex 2 was AAGCTTGAACTTGCCACTTCA
(sense: r(GCUUGAACUUGCCACUUCA)dTT; antisense
sequence: r(UGAAGUGGCAAGUUCAAGC)dTdT).
Table 1: Statistical significance (p values) for a panel of 
neuroendocrine markers in human tumours.
Gene BN vs PCa BN vs MET PCa vs MET
Ascl1 0.296481304 0.003042 0.00154356
Hes6 0.024247479 0.01678206 0.01129449
Nts 0.472811274 0.05652598 0.03387797
Nse 0.001424731 0.03568144 0.01538955
Chga 0.102607964 0.0783078 0.05591173
AR 0.209422779 0.05160438 0.04404816
Hes1 0.041737561 0.16434413 0.40890498
NeuroD1 0.210143163 0.10369964 0.06466747
Syt4 0.00753976 0.04080721 0.00655119
Asph 0.241306154 0.00261299 0.00148242
Atp11a 0.059113322 0.0058551 0.27651832
Ddc 0.307964378 0.01022954 0.00378398
Ngn1 0.266250502 0.28859185 0.4960235
Ngn2 0.069344987 0.06267247 0.03905491
Ngn3 0.270696485 0.03998213 0.08993646
Significance values were generated by comparing the fold-change in 
gene expression between expression levels in the dataset of 
Varambally et al., (2005) and examining benign (BN), localised 
prostate cancer (PCa) and metastatic (MET) samples. A two sample 
Student's t-Test with a one-tailed distribution was used to obtain the 
p-values.
Table 2: Primer sequences for quantitative real-time PCR validation.
Gene Primer sense Primer antisense
SDH TGGGAACAAGAGGGCATCTG CCACCACTGCATCAAATTCATG
GAPDH GCAAATTCCATGGCACCGT TCGCCCCACTTGATTTTGG
UBC ATTTGGGTCGCGGTTCTTG TGCCTTGACATTCTCGATGGT
TBP GAATATAATCCCAAGCGGTTTG ACTTCACATCACAGCTCCCC
Neuromedin/NT GAGGAGCTTGTTGCAAGAAGGA GCCCTGCTGTGACAGATTTTGT
Hes6 AGCTCCTGAACCATCTGCTC GACTCAGTTCAGCCTCAGGG
Ascl1 GAGCAGGAGCTTCTCGACTTC GATGCAGGTTGTGCGATCAC
Hes1 TGGAAATGACAGTGAAGCACCT GTTCATGCACTCGCTGAAGC
NeuroD1 CGCTGGAGCCCTTCTTTG GCGGACGGTTCGTGTTTG
DDC AAGCACAGCCATCAGGATTCA TGGACATGCTTGCGGATATAAG
Neurogenin 2 CGCATCAAGAAGACCCGTAG GTGAGTGCCCAGATGTAGTTGTG
Primers for quantitative real time polymerase chain reaction using Sybrgreen chemistry were designed using Primer Express software (Applied 
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Patients
A database encompassing patients undergoing radical
prostatectomy at Addenbrookes Hospital, Cambridge was
interrogated. Sections containing regions of normal, BPH,
PIN and cancer were classified by uro-pathologists within
specimens taken from 32 patients. The cancerous regions
were further sub-divided into Gleason Grade 3,4 and 5.
Duplicate cores were taken from within each section to
provide material corresponding to each Gleason Grade as
well as BPH, PIN and Normal material for each patient.
This material was arrayed on a tissue microarray (TMA).
Material was collected with full ethics approval from a
local ethics committee (MREC/01/4/061 and LREC 02/
281 M) and as part of the ProMPT Study: Molecular mech-
anisms and the development of novel treatment strategies
in progressing prostate cancer – Northern (and Bristol)
Prostate Cancer Collaborative).
Mice
Mouse materials were collected and processed as
described earlier [15]. This was conducted in compliance
with international guidelines as confirmed in the original
paper describing the model.
Tissue Microarray
Paraffin blocks from identified patients that had been
selected for construction of a tissue micro-array (TMA)
were cut using a standard microtome at 5 μm thickness
and stained with hematoxylin and eosin (H&E). Confir-
mation of tissue status (Gleason grades and BPH) was
conducted by an uro-pathologist, who assessed and
marked the blocks appropriately. 0.6 mm tissue cores
were cut and constructed according to pre-determined lay-
out.
Immunohistochemistry
For NT (Sigma), NTR2 (Acris Antibodies GmbH) and
Ascl1 (Aviva Systems Biology) antibodies, antigen
retrieval was performed in Tris-EDTA at pH 9.0 in a micro-
wave for 15 minutes. Blocking was performed using 1%
donkey serum in PBS for 1 hour. Primary antibody dilu-
tions were as follows: NT and Ascl1 were used at 1:100
and NTR2 at 1:500. Staining was performed using the
same blocking solution at 4°C overnight. After three
washes in PBS, a biotin-SP-AffiniPure donkey anti-rabbit
secondary antibody was applied at a dilution of 1:200 for
45 minutes. Visualization was achieved using an
VECTASTAIN Elite ABC kit (Vector Laboratories) for 45
minutes and colour was accomplished using 3,3'-diami-
nobenzidine (DAB) for 1 minute.
Immunostaining assessment
Following immunostaining protocols, the TMAs were
assessed to determine the degree of TMA core loss or dis-
ruption, which varied between the different TMAs. In
those cores that remained intact, immunostaining was
evaluated according to staining intensity. Scoring was per-
formed independently by two observers (one an inde-
pendent specialist uro-oncology pathologist) both
blinded to the TMA plan. Staining intensity for Ascl1,
NTR2 and NT were scored on a scale of 0–5, where 0
means no staining, 1 means minimal staining and 5
means maximum intensity. For clarity of presentation, the
staining was then classified into negative (0), low (1–2),
medium (3), high (4) and very high (5) intensity. The two
assessors compared scores and a consensus agreement was
reached on the staining intensity of each core.
Results and Discussion
We have previously shown that prostate cell-lines selected
for resistance to anti-androgens develop a neuroendo-
crine phenotype [4]. In the present study we attempted to
identify the transcriptional drivers of this neuroendocrine
signature. To do this we interrogated an expression array
dataset from a prostate-specific Cre-LoxP p53PE-/-; RbPE-/-
mouse model of prostate cancer which has neuroendo-
crine characteristics and which maintains androgen recep-
tor expression [15] (Figure 1). This material consisted of
expression data from five metastatic prostate epithelium
tumours from p53PE-/-; RbPE-/- mice and three normal pros-
tates from normal non-recombinant littermates. Two
hundred and forty genes were differentially expressed
with a z-scored significance level of 1 × 10-8 (B > 10).
Among those genes, 135 genes were down-regulated and
105 genes were up-regulated in the neoplasms (Figure
2A). As reported in the initial analysis of this array data by
Zhou et al [15], within this signature were 3 up-regulated
(Lmnb1, Pttg1 and Hnrpab) and 4 down-regulated tran-
scripts (Myh11, Actg2, Mylk and Cnn1), showing that our
reanalysis of the data successfully identified previously
validated transcription changes. Interestingly, there was
also a strong correlation between the gene expression
changes identified in the p53PE-/-; RbPE-/- mouse model and
gene expression profiles of human metastatic prostate
cancer samples (r = 0.52). There was no such correlation
when the p53PE-/-; RbPE-/- mouse model was compared to
expression profiles for benign or localised prostate cancer
(r = -0.02 and 0.12), suggesting that this model may spe-
cifically recapitulate metastatic prostate disease in
humans.
Using data from the Oncogenomics Normal Tissue gene
expression Database [19] we assessed the tissue specific
expression of the differentially expressed genes. By com-
paring the complete set of differentially expressed genes
obtained for the p53PE-/-; RbPE-/- mice with this normal tis-
sue expression dataset we observed an enrichment of tran-
scripts concordantly regulated in normal mouse brain and
the p53PE-/-; RbPE-/- tumours (Figure 2B). Taking a stringentPage 4 of 16
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p53PE-/-; RbPE-/- cancer model and normal brain expression
(r = 0.49–0.52). This is in contrast to other normal tissue
expression patterns which showed no correlation with the
genes differentially expressed in the p53PE-/-; RbPE-/- model
(e.g., the correlation between the p53PE-/-; RbPE-/- cancer
model and normal bladder expression was r = 0.01). This
suggests that as these prostate tumours develop they
assume some of the gene expression characteristics of neu-
rons (Figure 2B). These changes included the upregula-
tion of two established neuroendocrine markers, Chga
and Ddc (Figure 3B). In addition, two pro-neural bHLH
transcription factors Hes6 (M = 3.87, B = 7.17) and Ascl1
(also called Mash1, Ash1 and Hash1; M = 5.06, B = 10.65)
were also up-regulated (Figure 3A–B).
The implication of the expression signature from p53PE-/-;
RbPE-/- mouse tumours is that a transdifferentiation pro-
gram has been initiated by knocking out p53 and Rb. This
is reflected in the expression of neuroendocrine markers
and the change in levels of activator-type and repressor-
type bHLH transcription factors. Clearly this does not pro-
duce a pure neural lineage in the tumours since they con-
tinued to express the androgen receptor together with
cytokeratin 5, a basal cell marker, and cytokeratin 8, a
luminal epithelial cell marker [15].
We sought to test whether this change was also a hallmark
of androgen resistance in LNCaP cell-lines that were anti-
androgen resistant (LNCaP-Bic), or derived from castrate
resistant (C4-2) and osseous metastatic (C4-2b) mouse
xenografts. We compared the levels of previously reported
markers, neurotensin (NTS) and dopa decarboxylase
(DDC), as well activator-type bHLH transcription factors
(Ascl1, Hes6, NeuroD1 and Ngn2) using real-time PCR and
found that they were all elevated in the three resistant cell
lines (C4-2b>C4-2>LNCaP-Bic) compared to the parental
LNCaP cells (Figure 4A). For instance, Nts was 3500 fold
higher in C4-2b than the parental LNCaP cell line, Hes6
and NeuroD1 were 1200 and 2600 fold higher respec-
tively, whereas Ascl1 was increased 104 fold. Other mem-
bers of the neurogenin family of transcription factors
including Ngn1 and Ngn3 were also increased across the
cell lines but to a lesser degree than Ngn2 (data not
shown). The reduced expression of a repressor-type bHLH
factor such as Hes1 could account for these changes in the
expression of these neural markers, however we found no
change in the level of the Hes1 transcript across the differ-
ent cell lines (Figure 4A). The expression of Ddc, an estab-
lished neuroendocrine marker gene, was higher in the C4-
2b cells only. Overall, we found that neural transcripts
increased as the cell lines became more aggressive. To
examine the expression of Ascl1 and Hes6 at the protein
Script used to identify differentially expressed transcripts in expression array data for the prostate p53PE-/-; RbPE-/- mouse modelFigure 1
Script used to identify differentially expressed transcripts in expression array data for the prostate p53PE-/-; 
RbPE-/- mouse model. Data were pre-processed using the RMA (Robust Multichip Average) method, before fitting a linear 
model and applying Bayesian smoothing to identify differentially expressed genes between the normal and cancer samples.
library(limma)
library(affy)
library("mgu74av2")
targets<-readTargets()
tab <- ReadAffy(filenames=targets$filename)
reset<-rma(ab)
treatments <- factor(c(1,1,1,2,2,2,2,2,2),labels=c("normal","cancer"))
contrasts(treatments) <- cbind(CAvsNR=c(0,1))
design <- model.matrix(~treatments)
colnames(design) <- c("Cancer","Normal")
fit <- lmFit(eset,design)
cont.matrix <- cbind(Cancer=c(1,0),Normal=c(0,1))
fit2 <- contrasts.fit(fit, cont.matrix)
fit2 <- eBayes(fit2)
write.table(topTable(fit2, coef=2, adjust="fdr", n=24976), sep="\t", "allgenes.txt")Page 5 of 16
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Over-expressed transcripts in a conditional mouse model for metastatic prostate cancer coincide with those expressed in nor-mal cereb um/cerebellum adult tissuesFigur  2
Over-expressed transcripts in a conditional mouse model for metastatic prostate cancer coincide with those 
expressed in normal cerebrum/cerebellum adult tissues. (a) Hierarchical clustering of gene expression profiles from 
normal and prostate cancer tissues in p53PE-/-; RbPE-/- mice showing clusters of up and down-regulated genes. Heatmap colours 
represent relative mRNA expression as indicated in the colour key. (b) A heat map generated by hierarchical clustering of nor-
mal prostate, cerebrum and cerebellum adult tissue gene expression (Oncogenomics data) for genes identified as differentially 
expressed in the p53PE-/-; RbPE-/- prostate cancer mouse model. Differentially expressed genes in prostate cancer tissue from the 
p53PE-/-; RbPE-/- mouse coincide with those of normal adult tissue from cerebrum and cerebellum and not from the normal pros-
tate.
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Pro-neural and neuroendocrine transcripts are over-expressed in the Cre-Lox p53PE-/-; RbPE-/- knockout mouse model of pros-tate cancerFigur  3
Pro-neural and neuroendocrine transcripts are over-expressed in the Cre-Lox p53PE-/-; RbPE-/- knockout mouse 
model of prostate cancer. (a) Expression array data from the p53PE-/-; RbPE-/- mouse model is represented in a volcano plot. 
Transcripts up-regulated are shown in red and those down-regulated are indicated in blue. Pro-neural transcription factors, 
Hes6 and Ascl1, and neuroendocrine marker genes such us chromogranin A (Chga) and dopa decarboxylase (Ddc) are up-regu-
lated in the mouse prostate cancer tumours. Other genes previously shown to be associated with a molecular signature of 
metastasis in primary solid tumours were also differentially expressed. (b) Differentially expressed pro-neural and neuroendo-
crine genes in p53PE-/-; RbPE-/- prostate cancers from biological replicate array data are represented in a heatmap (red repre-
sents up-regulated genes and green indicates down-regulated genes).
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Pro-neural transcription factor expression is increased in more invasive/metastatic prostate cancer cell-linesFigur  4
Pro-neural transcription factor expression is increased in more invasive/metastatic prostate cancer cell-lines. 
(a) The expression of pro-neural and neuroendocrine transcripts was measured by quantitative RT-PCR using four different 
cell lines. In the bicalutamide resistant cells (black bars), the androgen-independent cells C4-2 (blue bars) and the androgen-
independent metastatic C4-2b cells (green bars) the expression of Nts, Ascl1 and Hes6 with metastatic potential of the lines. 
The cell line data is presented in order of metastatic potential in a xenograft model of prostate cancer (LNCaP on the left-hand 
side having limited metastatic potential progressing through to C4-2b with the potential to generate bone metastases upon 
implantation). Data is represented as fold change as comnpared with the parental LNCaP cell line (light blue bars with asterisk). 
Also there is expression of NeuroD1 and Neurogenin2 (Ngn2) in the metastatic cells but to a lesser degree. No changes in the 
expression of Hes1 were observed in any of the cell lines. All the data was normalized using the average of four housekeeping 
genes (Gapdh, Sdh, Ubc and Tbp) and the ratio against the parental line (purple bars) was plotted. A table with the Ct values 
obtained for each of the genes prior to analysis is provided (b) Immunohistochemistry for Ascl1 on paraffin embedded sections 
from LNCaP and bicalutamide-resistant LNCaP cell-lines.
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Hes6 regulates the transcription of other pro-neural factorsFigure 5
Hes6 regulates the transcription of other pro-neural factors. The transcription of Hes6 was silenced by siRNA tech-
nology using two different duplexes in both C4-2 (dark blue bars) and C4-2b (green bars) cells. Data is represented as fold 
change as comnpared with the parental LNCaP cell line (light blue bars with asterisk). No effect was observed when the scram-
bled RNA was used. Other transcripts such as Ascl1, Nts, NeuroD1 and Ngn2 were also affected by Hes6 knockdown, however 
no effect was observed when the Hes1 transcript was analyzed. As previously reported the levels of pro-neural transcription 
factors in the C4-2 and C4-2b lines are significantly elevated versus the LNCaP cell-line with only Hes1 levels largely 
unchanged.
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Pro-neural and neuroendocrine transcripts are over-expressed in metastatic human prostate cancerFigur  6
Pro-neural and neuroendocrine transcripts are over-expressed in metastatic human prostate cancer. (a) The 
transcription factors Ascl1 and Hes6 are increased in a small set of metastatic prostate cancers as well as the neuroendocrine 
markers neuron specific enolase (Nse) and dopa-decarboxylase (Ddc). Hes1 expression did not change whereas NeuroD1 was 
slightly increased in metastatic tissue. The AR expression in metastatic tissue was found to be subdivided in two groups. 
NeuroD1 and synaptotagmin4 (Syt4) were also found increased. (b) Pro-neural factors discriminate between primary carcinoma 
and metastasis in prostate cancer. Using clustering analysis, it was possible to discriminate between metastasis and primary 
tumours by the expression of the pro-neural/neuroendocrine markers Ascl1, Hes6, Ddc, and Nts in human prostate tissue.
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BMC Medical Genomics 2008, 1:17 http://www.biomedcentral.com/1755-8794/1/17level, paraffin embedded material from parental and
bicalutamide resistant cells was used. Hes6 protein was
barely detectable in the LNCaP line but was highly
expressed in the bicalutamide resistant cells (data not
shown). The localization of the protein in the LNCaP-Bic
cell line was mainly nuclear although some staining was
observed in the cytoplasm (data not shown). Ascl1 was
also highly expressed in the resistant cells (Figure 4B).
Based on reports that Hes6 can regulate the expression
and activity of a panel of other transcription factors
including Neurogenins and Ascl1, we went on to target
Hes6 with two different RNA interference duplexes in two
of the resistant cell-lines (C4-2 and C4-2b) (Figure 5).
This strategy led to a significant reduction (>80%) of Hes6
transcript levels in both lines but also induced the down-
regulation of Ascl1, Ngn2, Nts and NeuroD1 effectively
reversing the neuroendocrine phenotype. Ngn1 and Ngn3
levels were also reduced (data not shown). Hes1 expres-
sion was unaffected.
To determine whether the high expression of the pro-neu-
ral transcription factors Hes6 and Ascl1 in metastatic
mouse tumours extrapolated to human diseases, we uti-
lised a publicly available gene expression microarray data
set that included six benign, seven primary prostate can-
cers and six metastatic prostate cancers from human tissue
samples [28]. Ascl1 and Hes6 were highly expressed in all
the metastatic tissue samples (p-values 0.001 and 0.01
respectively) (Figure 6A/Table 1). Neuroendocrine mark-
ers such as neuron specific enolase (Nse) and dopa decar-
boxylase (Ddc) were over-expressed in most of the
metastatic samples, with p-values of 0.01 and 0.003
respectively for the transition from prostate cancer to
metastasis. Androgen receptor (AR) expression was ele-
vated in half of the metastatic samples and down-regu-
NTR2 expression increases progressively during the cancer development whereas NT and Ascl1 expression is upregulated at the BPH-PIN tra sitionFigure 7
NTR2 expression increases progressively during the cancer development whereas NT and Ascl1 expression is 
upregulated at the BPH-PIN transition. (a) Immunohistochemical analysis of prostate tissue microarrays comprising nor-
mal, BPH, PIN and adenocarcinomas. Sections were stained with anti-NT, anti-NTR2 or anti-Ascl1 antibodies. NTR2 immuno-
reactivity is most intense in PIN and carcinomas, in contrast NT and Ascl1 immunoreactivity is mostly observed in the 
carcinomas. (b-d) Histopathological score for each specific prostate tissue based on the immunoreactivity antibody staining.
AMONICRACNIPHPB LAMRON
Ascl1
NTR2
NT
Negative
Very low
Low
Medium
0
10
20
30
40
50
60
70
80
90
100
Normal BPH PIN G3 G4 G5
Pe
rc
en
ta
g
e 
(%
)
0
10
20
30
40
50
60
70
80
90
100
Normal BPH PIN G3 G4 G5
Pe
rc
en
ta
g
e 
(%
)
Negative
Low
Medium
High
Ascl1 immunoreactivity score NT immunoreactivity score
0
10
20
30
40
50
60
70
80
90
100
Normal BPH PIN G3 G4 G5
Negative
Low
Medium
High
Very high
Pe
rc
en
ta
g
e 
(%
)
NTR2 immunoreactivity score
A
B C DPage 11 of 16
(page number not for citation purposes)
BMC Medical Genomics 2008, 1:17 http://www.biomedcentral.com/1755-8794/1/17lated in the other half when compared to the benign
material (Figure 6A). Previously it has been reported that
the AR continues to be expressed during prostate cancer
progression and persists in a majority of patients with hor-
mone refractory disease [29,30]. Our observation that the
AR is upregulated in some metastatic samples and down-
regulated in others concords with the finding that in post-
mortem metastatic prostate tissue AR expression is more
heterogeneous with AR-positive and AR-negative popula-
tions of tumour cells between and within the same patient
[31].
Once again we were able to rule out derepression of differ-
entiation signals as a contributory factor to the neural
phenotype (e.g., through loss of Hes1 expression). Hes1
transcript levels remained unchanged in the clinical mate-
rial in agreement with our observations in the LNCaP cell-
line (Figure 6A). A member of the NeuroD family of pro-
neural transcription factors NeuroD1 was also up-regu-
lated in the metastatic samples (Figure 6A). The neuro-
genin family of pro-neural transcription factors was also
studied. Neurogenin 1 (Ngn1) did not significantly
change, neurogenin 3 (Ngn3) slightly increased in meta-
static tissue, and neurogenin 2 (Ngn2) was also up-regu-
lated in this tissue (P = 0.03) (Figure 6A). Some of the
targets we have previously identified as up-regulated after
long-term treatment with bicalutamide were also assessed
[4]. Of those, synaptotagmin 4 (Syt4) and aspartate beta-
hydroxylase (Asph) were increased in the transition from
localised prostate cancer to metastatic tumours with p-val-
ues of 0.006 and 0.001 respectively, whereas Atp11a was
highly increased in prostate cancer (P = 0.005) (Figure
6A). When a cluster analysis of the same data set was per-
formed, it was possible to discriminate between meta-
static and benign and primary tumours by using Ascl1,
Hes6, Ddc and Nts as marker genes (Figure 6B).
Table 3: Combinations of neuroendocrine biomarkers are enriched in specific malignant tissue types.
Hes6 tumour. hits Fgr Bgr p. value Reference
Colon 93 252 1534 2.74E-014 [26, 38]
Uterus 39 94 1692 3.24E-008 -
Rectosigmoid 12 27 1759 0.00043528 -
Rectum 12 32 1754 0.00303994 -
Hes6/DDC tumour. hits Fgr Bgr p. value Reference
Colon 197 252 1534 0 -
Rectosigmoid 21 27 1759 1.42E-009 -
Rectum 23 32 1754 5.03E-009 -
Liver 24 38 1748 1.65E-007 -
Kidney 75 214 1572 0.00040486 -
Stomach 5 8 1778 0.00476289 -
Hes6/CHGA tumour. hits Fgr Bgr p. value Reference
Colon 89 252 1534 0 -
Uterus 42 94 1692 6.80E-013 -
Endometrium 30 71 1715 6.50E-009 -
Rectosigmoid 13 27 1759 1.02E-005 -
Rectum 13 32 1754 0.00011383 -
Stomach 4 8 1778 0.00324489 -
NTS tumour. hits Fgr Bgr p. value Reference
Lung 36 108 1678 1.29E-010 [39]
Ovary 32 170 1616 0.00143643 [40]
Small intestine 3 6 1780 0.00226141 [41]
Ascl1 tumour. hits Fgr Bgr p. value Reference
Breast 40 317 1469 8.27E-008 -
Lung 20 108 1678 3.76E-007 [42, 43]
Ascl1/Hes6/NTS/DDC tumour. hits Fgr Bgr p. value Reference
Lung 15 108 1678 3.79E-006 -
Rectosigmoid 4 27 1759 0.00421239 -
A hypergeometric distribution was used to generate the p-values for each present tumour type. Tumour types mapping to less than 3 samples per 
group have been filtered out. References included do mention studies that relate the biomarker/s with human carcinoma tissue and most of them 
include very small sets of samples.
Neuroendocrine biomarkers enrich for specific malignant tissue types in a multi-tumour dataset. Samples from the ExpO expression dataset were 
clustered based on the expression of neuroendocrine genesets (Hes6, Hes6-Chga, Hes6-Ddc, Ascl1, Ascl1-Hes6-Nts-Ddc). Clusters were defined 
by a median expression level with a threshold level three-fold greater than the average intensity across all samples. These sample groups were 
tested for enrichment of malignant tissue type when compared to the complete dataset as background. The p-values were calculated using a hyper-
geometric distribution and represent the probability of obtaining the reported level of enrichment had the samples been selected at random.Page 12 of 16
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BMC Medical Genomics 2008, 1:17 http://www.biomedcentral.com/1755-8794/1/17We next sought to test the validity of Ascl1, neurotensin
receptor (NTR2) and NTS as cancer markers in clinical
prostate material from a distinct cohort of patients by
immunohistochemistry (Figure 7A). NTS and Ascl1 were
negative in around 70% of normal specimens becoming
detectable in around 70% of samples on the transition to
PIN and maintaining this expression level throughout
subsequent Gleason grades (Figures 7B and 7D). NTR2 by
contrast was detectable in around 95% normal samples at
medium to low levels. NTR2 staining intensity increased
progressively with tumour grade with moderate to very
high expression levels in 100% of samples at Gleason
Grade 5 (Figure 7C).
Ascl1 has previously been reported to be over-expressed in
small cell lung cancer, medullary thyroid tumours and
astrocytomas, amongst others. There has however been no
attempt to explore the power of these markers in cluster-
ing tumours at different organ sites from material col-
lected and array profiled in a standardised manner (Figure
8). The expression project for Oncology (ExpO) at Gene
Expression Omnibus provides that possibility by making
publicly available the complete raw expression array data-
sets for 1786 multi-tissue tumours specimens [32]. Using
Ddc, Nts, Hes6, and Ascl1 and combinations of these tran-
scripts we were able to segregate this large clinical collec-
tion in a statistically significant manner by tissue site
(Figure 9/Table 3). This implies that, in addition to pros-
tate cancer, these proteins may have some utility as novel
markers of colon, uterus, rectum, liver, endometrium and
breast. However, this requires further validation.
Conclusion
In conclusion, distinct prostatic tumour models and
material (cell-lines derived from human tumours, trans-
genic mouse tumours and patient samples) all display the
hallmarks of neural transdifferentiation during the pro-
gression to metastatic disease which was associated with a
change in the balance of activity and expression in favour
of activator-type bHLH transcription factors including
Hes6 and Ascl1. Similar changes are discernible in sub-
groups of tumours at other sites. Collectively this suggests
that impairing the activation of pro-neural transcription
factors may pay dividends in cancer treatment. However,
transcription factors are not conventionally druggable.
Nonetheless, antisense oligonucleotide therapy has
recently entered phaseII clinical trials to target a chaper-
one protein, clusterin [33]. Suicide gene therapy has also
been proposed in which a therapeutic gene, for example
Herpes Simplex Thymidine Kinase or E. Coli purine nucl-
eoside phosphorylase, under the control of promoters for
transcription factors exclusively over-expressed in cancer
cells such as Ascl1 is expressed and activates Ganciclovir to
induce cell cycle arrest [34-36]. In addition 'stapled' pep-
tides are being developed to disrupt protein-protein inter-
Script used to test the ability of pro-neural and neuroendo-crine transcrip s to s gregate tum urs based on organ site from a multi-tis ue canc r expressio  ar y datas tFigure 8
Script used to test the ability of pro-neural and neu-
roendocrine transcripts to segregate tumours based 
on organ site from a multi-tissue cancer expression 
array dataset. The DBI package within R was used to 
extract neuroendocrine gene profiles (205311_at:DDC, 
206291_at:NTS, 206940_s_at:POU4F1, 209985_s_at:ASCL1, 
209987_s_at:ASCL1, 209988_s_at:ASCL1, 
211341_at:POU4F1, 213768_s_at:ASCL1, 
214347_s_at:DDC, 226446_at:HES6, 228169_s_at:HES6, 
204697_s_at:CHGA). Each gene profile was scaled to it's 
median value across all samples and a Bioconductor Expres-
sion Set object created. The profiles were grouped into func-
tional gene sets.
run.hyper <- function(b, cond, levs=levels(cond), th=2){
  results <- NULL
  for(k in levs){
    if(sum(cond[b]==k) > th){
      row <- c(k,
               sum( cond[b]==k ), # hits, number of tumour type k  
             # samples in selected samples
               sum( cond==k ), # foreground, total number of   
                                                  # tumour type k samples in data set
               sum( cond!=k ),# total number of non tumour type k  
                                                 # samples in dataset
               sum( b ),          # sample size
               1-phyper(sum( cond[b]==k ), # p-value for enrichment
                        sum( cond==k ),
                        sum( cond!=k ),
                        sum( b )))
      if(is.null(results)){
        results <- rbind(row)
        colnames(results) <- c("tumour.type",
                               "hits",
                               "foreground",
                               "background",
                               "sample.size",
                               "p.value")
      }else{
        results <- rbind(results, row)
      }
    }
  }
  results
}
phyper.expo <- function(decide, pdat, th=2){
  
  results <- list()
  
  for(ci in colnames(pdat)){
    results[[ci]] <- list()
    results[[ci]]$up    <- run.hyper(decide==1,
                                     pdat[,ci],
                                     th=th)
    results[[ci]]$down  <- run.hyper(decide==-1,
                                     pdat[,ci],
                                     th=th)
    results[[ci]]$mixed <- run.hyper(decide!=0,
                                     pdat[,ci],
                                     th=th)
  }
  results
}Page 13 of 16
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BMC Medical Genomics 2008, 1:17 http://www.biomedcentral.com/1755-8794/1/17actions which may become relevant for targeting
transcriptional complexes as well [37]. In light of this
study and in combination with these new technologies we
may, in future, be capable of exploiting transcription fac-
tor activity to control cell fate and improve patient sur-
vival.
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Subgroups of different cancers can be identified using a proneural signatureFigu e 9
Subgroups of different cancers can be identified using a proneural signature. Expression vectors of neuroendocrine 
biomarkers across the 1786 sample ExpO data set are shown in the heatmap. This was generated using the heatmap function 
within Bioconductor. Each gene is scaled to its median intensity across all samples. Samples displaying a greater than 3 fold 
increase in expression for each of the neuroendocrine gene sets are highlighted with black bars above the heatmap. These sam-
ples were tested for enrichment of malignant tissue types (Table 3). Malignant tissue samples enriching proneural signature 
sample groups are highlighted as coloured bars at the top of the heatmap.
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